Determined DNA sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions

• US 6,242,250 B1
• Filed: 05/25/2000
• Issued: 06/05/2001
• Est. Priority Date: 03/21/1986
• Status: Expired due to Fees

• Current Assignee: Roche Molecular Systems (Roche Holding AG)
• Original Assignee: Institut Pasteur
• Inventors: Cole, Stewart, Streeck, Rolf E.
• Primary Examiner(s): SALIMI, ALI REZA
• Application Number:
  US09/577,493
• Time in Patent Office: 376 Days
• Field of Search: 435/320.1, 435/235.1, 435/5, 536/23.72, 536/23.1, 536/24.1, 514/44
• US Class Current: 435/320.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Q 1/708 for papilloma

Abstract

The invention concerns DNA fragments derived from the genomic DNA of HPV-33. These fragments are selected from the group of fragments extending between the nucleotide extremities defined hereafter in relation to the nucleotide-numbering in FIGS. 1a and 1b respectively:

76-556

543-864

867-2811

2728-3808

3326-3575

3842-4079

4198-5611

5516-8091.

The invention also relates to the use of these fragments as probes for the detection of HPV in tissue cultures.

Claims

1. A process for producing recombinant human papillomavirus-33 DNA comprising:

cloning into a suitable host a recombinant vector comprising at least one nucleotide sequence from human papillomavirus-33 DNA and a suitable vector,

wherein said at least one nucleotide sequence from human papillomavirus-33 DNA is inserted into said vector at a site permitting the cloning of said recombinant vector into a suitable host.

2. The process of claim 1, further comprising recovering the resultant cloned recombinant human papillomavirus-33 DNA.

3. The process of claim 1, wherein said host is a procaryotic microorganism.

4. The process of claim 1, wherein said at least one nucleotide sequence from human papillomavirus-33 DNA comprises a complete human papillomavirus-33 DNA sequence.

5. The process of claim 1, wherein said at least one nucleotide sequence from human papillomavirus-33 DNA comprises at least one fragment of a human papillomavirus-33 DNA sequence.

6. The process of claim 5, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 76-556, b) 543-864, c) 867-281 1, d) 2728-3808, e) 3326-3575, f) 3842-4079, g) 4198-5611, and h) 5516-7091.

7. The process of claim 6, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 4198-5611, and b) 5516-7091.

8. The process of claim 5, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 109-556, b) 573-864, c) 879-2811, d) 2749-3808, e) 3326-3575, f) 3842-4079, g) 4210-5611 and h) 5594-7091.

9. The process of claim 8, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 4210-5611 and b) 5594-7091.

10. The process of claim 5, wherein said fragment comprises a 78-base sequence identified as 78-1 in FIG. 3.

11. The process of claim 5, wherein said fragment comprises a 156-base sequence identified as 78-1 and 78-2 in FIG. 3.

12. The process of claim 5, herein said fragment comprises a nucleotide sequence extending from nucleotide 229 to nucleotide 404 of FIG 1A.

13. The process according to claim 2, wherein said process further comprises labeling the recovered resultant cloned recombinant human papillomavirus-33 DNA with a marker comprising at least one member selected from the group consisting of an enzyme, a radioactive compound, and a fluorescent compound.